Chemistry:Landipirdine

From HandWiki

Landipirdine (INN, USAN; developmental code names RO-5025181 and SYN-120) is a serotonin 5-HT2A and 5-HT6 receptor antagonist which was under development for the treatment of dementia and cognition disorders but was never marketed.[1][2][3] It is taken orally.[1] The drug was developed by Roche, Accorda Therapeutics, and Biotie Therapies.[1] It reached phase 2 clinical trials for dementia and phase 1 trials for cognition disorders prior to the discontinuation of its development in 2020.[1][2] Landipirdine was first described in the scientific literature by at least 2010.[4][5]

References

  1. ↑ 1.0 1.1 1.2 1.3 "Acorda Therapeutics". 9 March 2020. https://adisinsight.springer.com/drugs/800029826. 
  2. ↑ 2.0 2.1 "Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease". Expert Opinion on Investigational Drugs 24 (12): 1515–1528. 2015. doi:10.1517/13543784.2015.1102884. PMID 26548316. 
  3. ↑ "Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial". Parkinsonism & Related Disorders 114. September 2023. doi:10.1016/j.parkreldis.2023.105511. PMID 37532622. 
  4. ↑ "5-hydroxytryptamine subtype 6 receptor modulators: a patent survey". Expert Opinion on Therapeutic Patents 20 (9): 1171–1196. September 2010. doi:10.1517/13543776.2010.494661. PMID 20716023. 
  5. ↑ "5-HT6 receptor antagonists as potential therapeutics for cognitive impairment". Current Topics in Medicinal Chemistry 10 (2): 207–221. 2010. doi:10.2174/156802610790411036. PMID 20166958. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Landipirdine&oldid=4308921"